Jonathan D. Tward
Rating: 4.9 of 5
( out of 64 reviews )

Jonathan D. Tward, MD, PhD, FASTRO

Languages spoken: English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital South

Radiation Oncology
1950 Circle of Hope
Salt Lake City , UT 84112
801-581-2396
Get Directions

  • Jonathan Tward, MD, PhD is a tenured Professor in the Department of Radiation Oncology and an internationally recognized pioneer in artificial-intelligence (AI)–driven digital and molecular oncology. A major authority on prostate, bladder, and penile cancers, he also holds the Vincent P. and Janet Mancini Presidential Endowed Chair in Genitourinary Malignancies at Huntsman Cancer Institute (HCI).

    Dr. Tward directs the HCI Genitourinary Cancers Center (GUCC), coordinating nearly 100 investigators across 45 University of Utah or HCI departments and 21 interdisciplinary programs. Under his leadership, the Center has built an integrated digital-molecular ecosystem—linking multimodal imaging, high-throughput “omics” data, and electronic health records—to power AI-enabled discovery, prognostic and predictive biomarker development, and precision-oncology workflows. He guides the Center’s strategic vision and day-to-day operations, fostering multidisciplinary collaboration across patient care, community engagement, research, and philanthropy.

    A highly targeted radiation therapy specialist, Dr. Tward deploys cutting-edge technologies—including IMRT, IGRT, SBRT, and both low- and high-dose-rate brachytherapy—often enhanced by AI-based image segmentation and adaptive-planning algorithms. His translational research couples these platforms with molecular oncology, using genomic, transcriptomic, epigenetic, and proteomic profiling to discover and clinically validate biomarkers that forecast treatment response and long-term outcomes.

    Dr. Tward’s research portfolio spans machine-learning analytics, digital pathology, and large-scale comparative-effectiveness studies, and he serves as Principal Investigator on multiple investigator-initiated clinical trials that integrate molecular signatures and AI-guided treatment adaptation in real time. He has authored over 100 peer-reviewed publications, many at the intersection of AI, big-data science, and molecular biomarkers for genitourinary cancers.

    A committed advocate and educator, Dr. Tward is Utah’s State Captain for the American Society of Radiation Oncology (ASTRO), sits on National Comprehensive Cancer Network (NCCN) guideline panels for prostate, bladder, and penile cancers, and contributes to NCCN resource-stratification frameworks that embed digital and molecular solutions for low- and middle-income settings.

    Before joining HCI, Dr. Tward founded and led several pioneering e-commerce and health-tech companies—experience that now fuels his approach to digital and molecular oncology innovation. He earned a BS in Biology from UCLA, and both a PhD in Biochemistry and an MD from Tufts University, followed by a residency in Radiation Oncology at the University of Utah.

    Today, Dr. Tward’s hybrid expertise in clinical oncology, computational science, and molecular biomarker discovery positions him as a global leader shaping the future of AI-powered digital and molecular oncology.

    Specialties

    Patient Rating

    Rating: 4.9 out of 5
    4.9 /5
    ( out of 64 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    He has excellent people skills and expert in his specialty.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Care and treatment have been excellent.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Tward is very committed to understanding my situation and plotting a course of action in full partnership with me. My wife and I are very pleased with every aspect of the appointment with him.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Very simple, he is the best on the planet!!

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    He was friendly, took the time necessary to communicate thoroughly about the situation and was highly reassuring.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Excellent doctor and staff!

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Very kind and understanding. Explain procedures clearly to me and listened carefully to my questions.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    No one, in all aspects of what he does, could be better.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Tward and his staff spent over 2hrs with me discussing my treatment needs which have become complicated and multi-faceted. He and his staff are very aware of all treatment options out there (including clinical trials) but when I touched on a subject that was within his knowledge but outside his specific area of expertise (e.g. RO) he deferred to "the MO" for consultation. Exactly what you want from a physician (e.g. "I may know of it and have a solid opinion on it but my colleagues who specialize in that aspect of the treatment are better qualified to guide you"). I feel I have a care team at HCI not just one doctor which is what I need going forward.

  • Jonathan Tward, MD, PhD is a tenured Professor in the Department of Radiation Oncology and an internationally recognized pioneer in artificial-intelligence (AI)–driven digital and molecular oncology. A major authority on prostate, bladder, and penile cancers, he also holds the Vincent P. and Janet Mancini Presidential Endowed Chair in Genitourinary Malignancies at Huntsman Cancer Institute (HCI).

    Dr. Tward directs the HCI Genitourinary Cancers Center (GUCC), coordinating nearly 100 investigators across 45 University of Utah or HCI departments and 21 interdisciplinary programs. Under his leadership, the Center has built an integrated digital-molecular ecosystem—linking multimodal imaging, high-throughput “omics” data, and electronic health records—to power AI-enabled discovery, prognostic and predictive biomarker development, and precision-oncology workflows. He guides the Center’s strategic vision and day-to-day operations, fostering multidisciplinary collaboration across patient care, community engagement, research, and philanthropy.

    A highly targeted radiation therapy specialist, Dr. Tward deploys cutting-edge technologies—including IMRT, IGRT, SBRT, and both low- and high-dose-rate brachytherapy—often enhanced by AI-based image segmentation and adaptive-planning algorithms. His translational research couples these platforms with molecular oncology, using genomic, transcriptomic, epigenetic, and proteomic profiling to discover and clinically validate biomarkers that forecast treatment response and long-term outcomes.

    Dr. Tward’s research portfolio spans machine-learning analytics, digital pathology, and large-scale comparative-effectiveness studies, and he serves as Principal Investigator on multiple investigator-initiated clinical trials that integrate molecular signatures and AI-guided treatment adaptation in real time. He has authored over 100 peer-reviewed publications, many at the intersection of AI, big-data science, and molecular biomarkers for genitourinary cancers.

    A committed advocate and educator, Dr. Tward is Utah’s State Captain for the American Society of Radiation Oncology (ASTRO), sits on National Comprehensive Cancer Network (NCCN) guideline panels for prostate, bladder, and penile cancers, and contributes to NCCN resource-stratification frameworks that embed digital and molecular solutions for low- and middle-income settings.

    Before joining HCI, Dr. Tward founded and led several pioneering e-commerce and health-tech companies—experience that now fuels his approach to digital and molecular oncology innovation. He earned a BS in Biology from UCLA, and both a PhD in Biochemistry and an MD from Tufts University, followed by a residency in Radiation Oncology at the University of Utah.

    Today, Dr. Tward’s hybrid expertise in clinical oncology, computational science, and molecular biomarker discovery positions him as a global leader shaping the future of AI-powered digital and molecular oncology.

    Board Certification and Academic Information

    Academic Departments Radiation Oncology -Professor

    Education history

    Undergraduate Biology - UCLA B.S.
    Doctoral Training Biochemistry - Tufts University Ph.D.
    Professional Medical Medicine - Tufts University School of Medicine M.D.
    Internship Internal Medicine - University of Utah School of Medicine Intern
    Residency Radiation Oncology - University of Utah School of Medicine Resident
    Chief Resident Radiation Oncology - University of Utah School of Medicine Chief Resident

    Selected Publications

    Journal Article

    1. Chen J, Tward JD, Shrieve DC, Hitchcock Y (2008). Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002. American journal of clinical oncology, 31(5), 460-4. (Read full publication)
    2. Crosby MA, Tward JD, Szabo A, Lee CM, Gaffney D (2010). Does brachytherapy improve survival in addition to external beam radiation therapy in patients with high risk stage I and II endometrial carcinoma?. American journal of clinical oncology, 33(4), 364-9. (Read full publication)
    3. Cooke EW, Shrieve DC, Tward J (2012). Clinical versus pathologic staging for prostate adenocarcinoma: how do they correlate?. American journal of clinical oncology, 35(4), 364-8. (Read full publication)
    4. Jones G, Arthurs B, Kaya H, Macdonald K, Qin R, Fairbanks RK, Lamoreaux WT, Jawed I, Tward JD, Martincic D, Shivnani AT, Lee C (2013). Overall survival analysis of adjuvant radiation versus observation in stage I testicular seminoma: a surveillance, epidemiology, and end results (SEER) analysis. American journal of clinical oncology, 36(5), 500-4. (Read full publication)
    5. Tward JD, Shrieve, D (2007). Brachytherapy Monotherapy for Older Men with Prostate Cancer. Journal of aging and health, 3(5), 653-661.
    6. Price MJ, Li LT, Tward JD, Bublik I, McBride WH, Lavey R (1995). Effect of nicotinamide and pentoxifylline on normal tissue and FSA tumor oxygenation. Acta oncologica (Stockholm, Sweden), 34(3), 391-5. (Read full publication)
    7. Tward J, Glenn M, Pulsipher M, Barnette P, Gaffney (2007). Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma. Leukemia & lymphoma, 48(8), 1482-95. (Read full publication)
    8. Tward JD, Glenn M, Pulsipher M, Barnette P, Gaffney D (2007). Incidence, risk factors, and pathogenesis of second malignancies in patients with Non-Hodgkin lymphoma. Leukemia & lymphoma, 48(8), 1482-1495.
    9. Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney D (2006). The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer, 107(1), 108-15. (Read full publication)
    10. Macdonald OK, Lee CM, Tward JD, Chappel CD, Gaffney D (2006). Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer, 107(9), 2127-33. (Read full publication)
    11. Tward JD, Lee CM, Pappas LM, Szabo A, Gaffney DK, Shrieve D (2006). Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis. Cancer, 107(10), 2392-400. (Read full publication)
    12. Lee CM, Szabo A, Shrieve DC, Macdonald OK, Tward JD, Skidmore TB, Gaffney D (2007). Descriptive nomograms of adjuvant radiotherapy use and patterns of care analysis for stage I and II endometrial adenocarcinoma: A surveillance, epidemiology, and end results population study. Cancer, 110(9), 2092-100. (Read full publication)
    13. Hazard L, Tward JD, Szabo A, Shrieve D (2007). Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data. Cancer, 110(10), 2191-201. (Read full publication)
    14. Skidmore TB, Lee CM, Abbott TM, Wiggins RH 3rd, Anderson GE, Tward JD, Hitchcock (2008). Gorham disease of the mandible: radiographic findings and radiotherapy response. Ear, nose, & throat journal, 87(6), E4-7. (Read full publication)
    15. Jairath NK, Dal Pra A, Vince R Jr, Dess RT, Jackson WC, Tosoian JJ, McBride SM, Zhao SG, Berlin A, Mahal BA, Kishan AU, Den RB, Freedland SJ, Salami SS, Kaffenberger SD, Pollack A, Tran P, Mehra R, Morgan TM, Weiner AB, Mohamad O, Carroll PR, Cooperberg MR, Karnes RJ, Nguyen PL, Michalski JM, Tward JD, Feng FY, Schaeffer EM, Spratt D (2021). A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. European urology, 79(3), 374-383. (Read full publication)
    16. Philipson RG, Romero T, Wong JK, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Valle L, Chong N, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Klein EA, Tosoian JJ, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Kupelian PA, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Kishan A (2021). Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. European urology, 80(2), 142-146. (Read full publication)
    17. Barney BM, Hitchcock YJ, Sharma P, Shrieve DC, Tward J (2011). Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head & neck, 33(5), 645-9. (Read full publication)
    18. Lavey RS, Taylor JM, Tward JD, Li LT, Nguyen AA, Chon Y, McBride W (1994). The extent, time course, and fraction size dependence of mouse spinal cord recovery from radiation injury. International journal of radiation oncology, biology, physics, 30(3), 609-17. (Read full publication)
    19. Hitchcock YJ, Tward JD, Szabo A, Bentz BG, Shrieve D (2009). Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. International journal of radiation oncology, biology, physics, 73(3), 779-88. (Read full publication)
    20. Vern-Gross TZ, Shivnani AT, Chen K, Lee CM, Tward JD, MacDonald OK, Crane CH, Talamonti MS, Munoz LL, Small W J (2011). Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis. International journal of radiation oncology, biology, physics, 81(1), 189-98. (Read full publication)
    21. Erickson BA, Demanes DJ, Ibbott GS, Hayes JK, Hsu IC, Morris DE, Rabinovitch RA, Tward JD, Rosenthal S (2011). American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of high-dose-rate brachytherapy. International journal of radiation oncology, biology, physics, 79(3), 641-9. (Read full publication)
    22. Burt LM, Shrieve DC, Tward J (2014). Stage presentation, care patterns, and treatment outcomes for squamous cell carcinoma of the penis. International journal of radiation oncology, biology, physics, 88(1), 94-100. (Read full publication)
    23. Tward JD, Jarosek S, Chu H, Thorpe C, Shrieve DC, Elliott (2016). Time Course and Accumulated Risk of Severe Urinary Adverse Events After High- Versus Low-Dose-Rate Prostate Brachytherapy With or Without External Beam Radiation Therapy. International journal of radiation oncology, biology, physics, 95(5), 1443-1453. (Read full publication)
    24. Tward J, Lenz L, Flake DD II,, Rajamani S, Olsson C, Kapoor DA, Mantz C, Liauw SL, Antic T, Shore N, Albertson D, Henderson J, Lee SP, Gay HA, Michalski J, Hung A, Raben D, Garraway I, Lewis MS, Nguyen PL, Marshall DT, Brawer MK, Stone S, Cohen (2021). The Clinical Cell-Cycle Risk (CCR) score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation. International journal of radiation oncology, biology, physics, 113(1), 66-76. (Read full publication)
    25. Furie BC, Ratcliffe JV, Tward J, Jorgensen MJ, Blaszkowsky LS, DiMichele D, Furie (1997). The gamma-carboxylation recognition site is sufficient to direct vitamin K-dependent carboxylation on an adjacent glutamate-rich region of thrombin in a propeptide-thrombin chimera. The Journal of biological chemistry, 272(45), 28258-62. (Read full publication)
    26. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward J (2008). The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. The Journal of clinical endocrinology and metabolism, 93(2), 504-15. (Read full publication)
    27. Johnson SB, Parsons M, Dorff T, Moran MS, Ward JH, Cohen SA, Akerley W, Bauman J, Hubbard J, Spratt DE, Bylund CL, Swire-Thompson B, Onega T, Scherer LD, Tward J, Fagerlin (2021). Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report. Journal of the National Cancer Institute, 114(7), 1036-1039. (Read full publication)
    28. Ly D, Bagshaw HP, Anker CJ, Tward JD, Grossmann KF, Jensen RL, Shrieve D (2015). Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. Journal of neurosurgery, 123(2), 395-401. (Read full publication)
    29. Frandsen J, Orton A, Jensen R, Colman H, Cohen AL, Tward J, Shrieve DC, Suneja (2018). Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. Journal of neurosurgery, 128(4), 1133-1138. (Read full publication)
    30. O'Neil BB, Presson A, Gannon J, Stephenson RA, Lowrance W, Dechet CB, Tward JD, Myers JB, Brant W (2014). Climacturia after definitive treatment of prostate cancer. The Journal of urology, 191(1), 159-63. (Read full publication)
    31. Bassett MR, Santiago-Lastra Y, Stoffel JT, Goldfarb R, Elliott SP, Pate SC, Broghammer JA, Gaither T, Breyer BN, Vanni AJ, Voelzke BB, Erickson BA, McClung CD, Presson AP, Tward JD, Myers JB, Neurogenic Bladder Research Group., Trauma and Urologic Reconstructive Network of Surgeons (2017). Urinary Diversion for Severe Urinary Adverse Events of Prostate Radiation: Results from a Multi-Institutional Study. The Journal of urology, 197(3 Pt 1), 744-750. (Read full publication)
    32. Du K, Zhang C, Presson AP, Tward JD, Brant WO, Dechet C (2017). Orgasmic Function after Radical Prostatectomy. The Journal of urology, 198(2), 407-413. (Read full publication)
    33. Wang B, Tward JD, Salter B (2012). An evaluation of interference of inflatable penile prostheses with electromagnetic localization and tracking system. Medical physics, 39(8), 4807-11. (Read full publication)
    34. Szegedi M, Boehm C, Paxton A, Rassiah-Szegedi P, Sarkar V, Zhao H, Su F, Kokeny KE, Lloyd S, Tward J, Salter B (2020). Comparison of transperineal ultrasound image guidance technique to transabdominal technique for prostate radiation therapy. Medical physics, 47(12), 6113-6121. (Read full publication)
    35. Hitchcock YJ, Bentz BG, Sharma PK, Fang C, Tward JD, Pappas L, Chen J, Hayes JK, Shrieve D (2007). Planned neck dissection after definitive radiotherapy or chemoradiation for base of tongue cancers. Otolaryngology--head and neck surgery, 137(3), 422-7. (Read full publication)
    36. Macdonald OK, Lee RJ, Snow G, Lee CM, Tward JD, Middleton AW, Middleton GW, Sause W (2007). Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer. Urology, 69(2), 295-9. (Read full publication)
    37. Ghia AJ, Shrieve DC, Tward J (2010). Adjuvant radiotherapy use and patterns of care analysis for margin-positive prostate adenocarcinoma with extracapsular extension: postprostatectomy adjuvant radiotherapy: a SEER analysis. Urology, 76(5), 1169-74. (Read full publication)
    38. Merriman J, Tward J, Albertson D, Dechet C, Agarwal (2016). Durable Response to Treatment With Combination Radiotherapy and High-dose Interleukin-2 in Metastatic Chromophobe Variant Renal Cell Carcinoma. Journal of immunotherapy (Hagerstown, Md., 39(2), 101-3. (Read full publication)
    39. Mayer EN, Tward JD, Bassett M, Lenherr SM, Hotaling JM, Brant WO, Lowrance WT, Myers J (2017). Management of Radiation Therapy Oncology Group grade 4 urinary adverse events after radiotherapy for prostate cancer. BJU international, 119(5), 700-708. (Read full publication)
    40. Ravi P, Pond GR, Diamantopoulos LN, Su C, Alva A, Jain RK, Skelton WP 4th, Gupta S, Tward JD, Olson KM, Singh P, Grunewald CM, Niegisch G, Lee JL, Gallina A, Bandini M, Necchi A, Mossanen M, McGregor BA, Curran C, Grivas P, Sonpavde G (2021). Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. BJU international, 128(5), 607-614. (Read full publication)
    41. Lin DW, Crawford ED, Keane T, Evans B, Reid J, Rajamani S, Brown K, Gutin A, Tward J, Scardino P, Brawer M, Stone S, Cuzick (2018). Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urologic oncology, 36(6), 310.e7-310.e13. (Read full publication)
    42. Tward JD, Cachoeira CV, Salama ME, Lee RJ, Bowen G, Perkins SL, Glenn M, Confer M, Gaffney D (2009). Survival and recurrence in nonmycosis fungoides primary cutaneous lymphoma. Cancer journal (Sudbury, Mass.), 15(1), 87-92. (Read full publication)
    43. Barney B, Tward JD, Skidmore T, Gaffney D (2009). Does radiotherapy or lymphadenectomy improve survival in endometrial stromal sarcoma?. International journal of gynecological cancer, 19(7), 1232-8. (Read full publication)
    44. Ghia AJ, Gonzalez VJ, Tward JD, Stroup AM, Pappas L, Gaffney D (2011). Primary vaginal cancer and chemoradiotherapy: a patterns-of-care analysis. International journal of gynecological cancer, 21(2), 378-84. (Read full publication)
    45. Bagshaw HP, Pappas LM, Kepka DL, Tward JD, Gaffney D (2014). Patterns of care with brachytherapy for cervical cancer. International journal of gynecological cancer, 24(9), 1659-64. (Read full publication)
    46. Rassiah-Szegedi P, Wang B, Szegedi M, Tward J, Zhao H, Huang YJ, Sarkar V, Shrieve D, Salter (2011). Individualized margins for prostate patients using a wireless localization and tracking system. Journal of applied clinical medical physics, 12(3), 3516. (Read full publication)
    47. Zhao H, Sarkar V, Wang B, Rassiah-Szegedi P, Szegedi M, Jessica Huang Y, Huang L, Tward J, Salter (2019). Calculation of delivered composite dose from Calypso tracking data for prostate cancer: And subsequent evaluation of reasonable treatment interruption tolerance limits. Journal of applied clinical medical physics, 20(8), 105-113. (Read full publication)
    48. Canter DJ, Freedland S, Rajamani S, Latsis M, Variano M, Halat S, Tward J, Cohen T, Stone S, Schlomm T, Bishoff J, Bardot (2020). Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy. Prostate cancer and prostatic diseases, 23(1), 102-107. (Read full publication)
    49. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead D (2012). Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network, 10(9), 1081-7. (Read full publication)
    50. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M, National comprehensive cancer network (2013). Prostate cancer, version 1.2014. Journal of the National Comprehensive Cancer Network, 11(12), 1471-9. (Read full publication)
    51. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M, National Comprehensive Cancer Network (2014). Prostate cancer, version 2.2014. Journal of the National Comprehensive Cancer Network, 12(5), 686-718. (Read full publication)
    52. Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass D (2016). Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network, 14(1), 19-30. (Read full publication)
    53. Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith (2016). NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. Journal of the National Comprehensive Cancer Network, 14(10), 1213-1224. (Read full publication)
    54. Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski L (2017). Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 15(10), 1240-1267. (Read full publication)
    55. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla (2020). Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 18(3), 329-354. (Read full publication)
    56. Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, D'Amico AV, Davis BJ, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Horwitz EM, Ippolito JE, Kuettel MR, Lang JM, McKay R, McKenney J, Netto G, Penson DF, Pow-Sang JM, Reiter R, Richey S, Roach Iii M, Rosenfeld S, Shabsigh A, Spratt DE, Teply BA, Tward J, Shead DA, Freedman-Cass D (2021). NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network, 19(2), 134-143. (Read full publication)
    57. Hazard LJ, Tward JD, Shrieve D (2008). Adjuvant EBRT improves survival in patients with lymph-node-negative pancreatic cancer. Nature clinical practice. Oncology, 5(8), 438-9. (Read full publication)
    58. Tward JD, O'Neil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, Agarwal N, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet (2020). Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. Clinical genitourinary cancer, 18(4), 274-283.e5. (Read full publication)
    59. McComas K, Agarwal N, Bowen G, Maughan BL, Tward J (2020). Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell Carcinoma. In Press. Available online at DOI: https://doi.org/10.1016/j.clgc.2020.02.007. Clinical genitourinary cancer,
    60. Tward JD, Schlomm T, Bardot S, Canter DJ, Scroggins T, Freedland SJ, Lenz L, Flake DD 2nd, Cohen T, Brawer MK, Stone S, Bishoff (2021). Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy. Clinical genitourinary cancer, 19(4), 296-304.e3. (Read full publication)
    61. Thomas JJ, Tward J (2021). Stage Presentation, Care Patterns, Treatment Outcomes, and Impact of Radiotherapy on Overall Survival for Adrenocortical Carcinoma. Clinical genitourinary cancer, 19(5), 417-424. (Read full publication)
    62. Tward AE, Tward J (2021). The Stage at Presentation and Oncologic Outcomes for Agent Orange Exposed and Non-Exposed United States Veterans Diagnosed With Prostate Cancer. Clinical genitourinary cancer, 19(4), 369-369.e7. (Read full publication)
    63. Hutten RJ, Parsons MW, Weil CR, Tward JD, Lloyd S, Sanchez A, Lester-Coll N, Johnson S (2021). Temporal Trends and Predictors in Diagnosing Pathologic Node-Positive Prostate Cancer in Clinically Node-Negative Patients. Clinical genitourinary cancer, 19(6), e360-e366. (Read full publication)
    64. Tward (2018). The case for nonsurgical therapy of nonmetastatic penile cancer. Nature reviews. Urology, 15(9), 574-584. (Read full publication)
    65. O'Neil B. , Brant W.O. , Slack S.D., Tward J.D., Myers J.B (2011). Penile Cancer: Contemporary Considerations in Management of Local Disease. Current urology, 5(2), 62-71.
    66. Sarkar V, Lloyd S, Paxton A, Huang L, Su FC, Tao R, Tward J, Zhao H, Salter (2018). Daily breathing inconsistency in pancreas SBRT: a 4DCT study. Journal of gastrointestinal oncology, 9(6), 989-995. (Read full publication)
    67. Tward JD, Kokeny KE, Shrieve D (2013). Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival. Practical radiation oncology, 3(3), 234-240. (Read full publication)
    68. Salter BJ, Szegedi M, Boehm C, Sarkar V, Rassiah-Szegedi P, Wang B, Zhao H, Huang J, Huang L, Kokeny K, Tward J (2017). Comparison of 2 transabdominal ultrasound image guidance techniques for prostate and prostatic fossa radiation therapy. Practical radiation oncology, 7(2), e99-e107. (Read full publication)
    69. Solanki AA, Savir-Baruch B, Liauw SL, Michalski J, Tward JD, Vapiwala N, Teoh EJ, LOCATE study group (2020). 18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE. Practical radiation oncology, 10(5), 354-362. (Read full publication)
    70. Usera BM, Creveling P, Tward J (2020). Impact and Outcomes of Pretreatment Total Serum Testosterone on Localized Prostate Cancer Patients. Prostate cancer, 2020, 8357452. (Read full publication)
    71. Tward JD, Poppe MM, Hitchcock YJ, O'Neil B, Albertson DJ, Shrieve D (2018). Demographics, stage distribution, and relative roles of surgery and radiotherapy on survival of persons with primary prostate sarcomas. Cancer medicine, 7(12), 6030-6039. (Read full publication)
    72. Lindsay M. Burt, Matthew Poppe, Kristine E. Kokeny, David K. Gaffney, Dennis C. Shrieve, Jonathan D Twar (2017). Comparison of Treatment Modalities for Breast Cancer Arising In Hodgkin's Lymphoma Survivors. Journal of radiation oncology, 6(1), 65-72.
    73. Aaron E. Wagner, Amol J. Ghia, Dennis C. Shrieve, Kristine E. Kokeny, William T. Lowrance, Jonathan D. Twar (2014). Adjuvant radiotherapy after prostatectomy: have randomized clinical trials had any impact?. Journal of radiation oncology, 3(4), 387-394.
    74. Jason J Schwartz, Heather F Thiesset, William R Hutson, Lisa Hazard, Jonathan Tward, James Carlisl (2013). Complete Resolution of a Malignant Biliary Stricture Using Combined Neoadjuvant Chemoradiation and Brachytherapy Boost Prior to Orthotopic Liver Transplantation. Journal of liver, 2(2),
    75. Ghia AJ, Tward JD, Anker CJ, Boucher KM, Jensen RL, Shrieve D (2014). Radiosurgery for melanoma brain metastases: the impact of hemorrhage on local control. Journal of radiosurgery and SBRT, 3(1), 43-50. (Read full publication)
    76. Wagner AE, Chen A, Anker CJ, Tward JD, Ghia AJ, Jensen RL, Shrieve D (2014). Stereotactic radiosurgery for a single brain metastasis: factors impacting control. Journal of radiosurgery and SBRT, 3(2), 111-121. (Read full publication)
    77. Frandsen J, Orton A, Shrieve D, Tward (2017). Risk of Death from Prostate Cancer with and without Definitive Local Therapy when Gleason Pattern 5 is Present: A Surveillance, Epidemiology, and End Results Analysis. Cureus, 9(7), e1453. (Read full publication)
    78. Greenberg S, Tward J, O'Neil (2019). Germline Variants in Highly Selected Patients With Prostate Cancer. JAMA oncology, 5(9), 1368-1369. (Read full publication)
    79. Gonzalez VJ, Hullett CR, Burt L, Rassiah-Szegedi P, Sarkar V, Tward JD, Hazard LJ, Huang YJ, Salter BJ, Gaffney D (2017). Impact of prone versus supine positioning on small bowel dose with pelvic intensity modulated radiation therapy. Advances in radiation oncology, 2(2), 235-243. (Read full publication)
    80. Burt LM, Shrieve DC, Tward J (2018). Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database. Advances in radiation oncology, 3(2), 170-180. (Read full publication)
    81. Greenberg SE, Hunt TC, Ambrose JP, Lowrance WT, Dechet CB, O'Neil BB, Tward J (2021). Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion. JCO precision oncology, 5, (Read full publication)
    82. Kishan AU, Karnes RJ, Romero T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Huland H, Tran PT, Martin S, Martínez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Chang AJ, Pisansky TM, Choo R, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, D'Amico AV, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki (2021). Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA network open, 4(7), e2115312. (Read full publication)
    83. Hutten RJ, Weil CR, Tward JD, Lloyd S, Johnson S (2021). Patterns of Care and Treatment Outcomes in Locoregional Squamous Cell Carcinoma of the Prostate. European urology open science, 23, 30-33. (Read full publication)
    84. Wang KM, Rickards AJ, Bingham T, Tward JD, Price R (2022). Technical note: Evaluation of a silicone-based custom bolus for radiation therapy of a superficial pelvic tumor. Journal of applied clinical medical physics, 23(4), e13538. (Read full publication)
    85. Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Tosoian JJ, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Jiang T, Ma TM, Xiang M, Philipson R, Chang A, Kupelian PA, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Boutros PC, Horwitz EM, Tendulkar RD, Spratt DE, Romero (2022). Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. JAMA oncology, 8, e216871. (Read full publication)
    86. Kraus RD, Weil CR, Wells S, Tward JD, Groundland JS, Jones KB, Cannon D (2021). Radiation Therapy in Conjunction With Surgical Stabilization of Impending or Pathologic Fractures Secondary to Metastasis: Is There a Difference Between Single and Multifraction Regimens?. Advances in radiation oncology, 7(2), 100795. (Read full publication)
    87. Hutten R, Tward J (2022). Nomograms for Metastasis-Free and Overall Survival for Pathologically Node Positive Prostate Cancer Patients Treated With or Without Radiation Therapy Plus Short-Term ADT. Clinical genitourinary cancer, 20, e263-e269. (Read full publication)
    88. Peoples AR, Oswald LB, Ose J, Daniels B, Himbert C, Hathaway CA, Gigic B, Kirchhoff AC, Lin T, Grossman D, Tward J, Varghese TK Jr, Figueiredo JC, Toriola AT, Beck A, Scaife C, Shibata D, LaStayo P, Gonzalez B, Salas K, Ashworth A, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich C (2022). Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions. The Journal of rural health, 38(4), 886-899. (Read full publication)
    89. Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples A (2022). Factors associated with changes in exercise behaviors during the COVID-19 pandemic. Cancer causes & control, 33(7), 939-950. (Read full publication)
    90. Hutten R, Khouri A, Parsons M, Tward A, Wilson T, Peterson J, Morrell G, Dechet C, O'Neil B, Schmidt B, Kokeny K, Lloyd S, Cannon D, Tward J, Sanchez A, Johnson (2022). The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. Clinical genitourinary cancer, 20(6), e453-e459. (Read full publication)
    91. Patel SA, Ma TM, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, DeWeese TL, Tilki D, Ciezki JP, Karnes RJ, Nickols NG, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Boutros PC, Romero T, Horwitz EM, Tendulkar RD, Steinberg ML, Spratt DE, Xiang M, Kishan A (2023). External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis. International journal of radiation oncology, biology, physics, 115(3), 645-653. (Read full publication)
    92. Rock CB, Chipman JJ, Parsons MW, Weil CR, Hutten RJ, Tao R, Tward JD, Shah HR, Hu B, Stephens DM, Gaffney D (2022). Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy. Advances in radiation oncology, 7(6), 101035. (Read full publication)
    93. Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney D (2023). Secondary malignancies in non-Hodgkin lymphoma survivors: 40¿years of follow-up assessed by treatment modality. Cancer medicine, 12(3), 2624-2636. (Read full publication)
    94. Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Berardi RA, Shead DA, Freedman-Cass D (2022). NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023. Journal of the National Comprehensive Cancer Network, 20(12), 1288-1298. (Read full publication)
    95. Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski L (2022). NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. Journal of the National Comprehensive Cancer Network, 20(8), 866-878. (Read full publication)
    96. Spratt DE, Tang S, Sun Y, Huang HC, Chen E, Mohamad O, Armstrong AJ, Tward JD, Nguyen PL, Lang JM, Zhang J, Mitani A, Simko JP, DeVries S, van der Wal D, Pinckaers H, Monson JM, Campbell HA, Wallace J, Ferguson MJ, Bahary JP, Schaeffer EM, Consortium NPCA, Sandler HM, Tran PT, Rodgers JP, Esteva A, Yamashita R, Feng F (2023). Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. (Read full publication)
    97. Fenlon JB, Nelson G, Teague KM, Coleman S, Shrieve D, Tward (2023). A Dosimetric Correlation Between Radiation Dose to Bone and Reduction of Hemoglobin Levels After Radiotherapy for Prostate Cancer. International journal of radiation oncology, biology, physics, 118(1), 85-93. (Read full publication)
    98. Hutten RJ, Weil CR, King AJ, Barney B, Bylund CL, Fagerlin A, Gaffney DK, Gill D, Scherer L, Suneja G, Tward JD, Warner EL, Werner TL, Whipple G, Evans J, Johnson S (2023). Multi-Institutional Analysis of Cancer Patient Exposure, Perceptions, and Trust in Information Sources Regarding Complementary and Alternative Medicine. JCO oncology practice, 19(11), OP2300179. (Read full publication)
    99. Hutten RJ, Odei B, Johnson SB, Tward J (2024). Validation of the Combined Clinical Cell-Cycle Risk Score to Prognosticate Early Prostate Cancer Metastasis From Biopsy Specimens and Comparison With Other Routinely Used Risk Classifiers. JCO precision oncology, 8, e2300364. (Read full publication)
    100. Spratt DE, Tang S, Sun Y, Huang HC, Chen E, Mohamad O, Armstrong AJ, Tward JD, Nguyen PL, Lang JM, Zhang J, Mitani A, Simko JP, DeVries S, van der Wal D, Pinckaers H, Monson JM, Campbell HA, Wallace J, Ferguson MJ, Bahary JP, Schaeffer EM, Sandler HM, Tran PT, Rodgers JP, Esteva A, Yamashita R, Feng F (2023). Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. NEJM evidence, 2(8), EVIDoa2300023. (Read full publication)
    101. Sung D, Schmidt B, Tward J (2024). The Ability of the STAR-CAP Staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial Treatment of M0 Prostate Cancer. Clinical genitourinary cancer, (Read full publication)
    102. Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Shead DA, Snedeker J, Freedman-Cass D (2023). Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 21(10), 1067-1096. (Read full publication)
    103. Tward JD, Lenz L, Gutin A, Clegg W, Kasten CR, Finch R, Cohen T, Michalski J, Kishan A (2024). Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer. JCO precision oncology, 8, e2300722. (Read full publication)
    104. Aßmann ES, Ose J, Hathaway CA, Oswald LB, Hardikar S, Himbert C, Chellam V, Lin T, Daniels B, Kirchhoff AC, Gigic B, Grossman D, Tward J, Varghese TK Jr, Shibata D, Figueiredo JC, Toriola AT, Beck A, Scaife C, Barnes CA, Matsen C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Grady WM, Schneider M, Dinkel A, Islam JY, Gonzalez BD, Otto AK, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples A (2024). Risk factors and health behaviors associated with loneliness among cancer survivors during the COVID-19 pandemic. Journal of behavioral medicine, 47(3), 405-421. (Read full publication)
    105. Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Michalski J, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Stewart T, Sundi D, Tollefson M, Tward J, Wright JL, Cassara CJ, Gurski L (2024). NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network, 22(4), 216-225. (Read full publication)
    106. Roach E, Hutten R, Johnson S, Suneja G, Tward J, Petereit D, Gaffney (2024). The impact of a positive COVID-19 test on timeliness of radiation in patients receiving brachytherapy. Brachytherapy, 23(3), 360-367. (Read full publication)
    107. Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Karnes RJ, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Szmulewitz R, Teply BA, Tward J, Valicenti R, Wong JK, Snedeker J, Freedman-Cass D (2024). NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network, 22(3), 140-150. (Read full publication)
    108. Tward JD, Huang HC, Esteva A, Mohamad O, van der Wal D, Simko JP, DeVries S, Zhang J, Joun S, Showalter TN, Schaeffer EM, Morgan TM, Monson JM, Wallace JA, Bahary JP, Sandler HM, Spratt DE, Rodgers JP, Feng FY, Tran P (2024). Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology. JCO precision oncology, 8, e2400145. (Read full publication)
    109. Lee H, Shen J, Fadlullah MZ, Neibling A, Hanson C, Ampaw E, Lin T, Larsen M, Lloyd J, Maughan BL, Swami U, Gupta S, Tward J, Johnson SB, O'Neil B, Schmidt B, Dechet CB, Haaland B, Wang L, Tan AC, Kohli (2025). Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer. Clinical proteomics, 22(1), 13. (Read full publication)
    110. Galarza Fortuna GM, Grass D, Maughan BL, Jain RK, Dechet C, Beck J, Schuetz E, Sanchez A, O'Neil B, Poch M, Li R, Lloyd S, Tward J, Phunrab T, Hawks JL, Swami U, Boucher KM, Agarwal N, Gupta (2025). Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). Journal for immunotherapy of cancer, 13(3), (Read full publication)
    111. Tward J, Lloyd S, Johnson S, Dechet C, Nei BO, Maughan B, Swami U, Gupta S, Sanchez A, Kokeny K, Agarwal (2025). A Phase 2 Trial of Radium(223) and Stereotactic Ablative Radiation Therapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR Study. International journal of radiation oncology, biology, physics, (Read full publication)
    112. Sung D, Sanchez A, Tward J (2023). Successful Salvage Brachytherapy after Infusion of Gold AuroShell Nanoshells for Localized Prostate Cancer in a Human Patient. Advances in radiation oncology, 8(4), 101202. (Read full publication)
    113. Li X, Bhagroo S, Su FC, Rahimi R, Tward (2025). Enhancing inguinal tumor treatment outcomes with a customized 3D-printed bolus. Journal of applied clinical medical physics, 26(7), e70175. (Read full publication)

    Review

    1. Tward J (2015). Editorial Review of: A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial. 1(1),
    2. Zamboglou C, Doncker W, Christoforou AT, Arcangeli S, Berlin A, Blanchard P, Bauman G, Campi R, Castro E, Choudhury A, Pra AD, Draulans C, Desai N, Ferentinos K, Francolini G, Gillessen S, Grosu AL, Rivas JG, Hoelscher T, Hruby G, Jereczek-Fossa BA, Kamran S, Kasivisvanathan V, Kishan AU, Kounnis V, Loblaw A, Martin J, Mastroleo F, Merseburger AS, Miszczyk M, Mohamad O, Ost P, Papatsoris A, Peeken JC, Sanguedolce F, Sargos P, Schmidt-Hegemann N, Seibert TM, Shelan M, Siva S, Soeterik TFW, Spratt DE, Stenzl A, Strouthos I, Sutera P, Supiot S, Tilki D, Tran PT, Tree AC, Tward J, Ürün Y, Vapiwala N, Waddle MR, Wegener E, Zilli T, Murthy V, Thieme AH, Spohn (2025). oDigital pathology biomarkers for guiding radiotherapy-based treatment concepts in prostate cancer - a systematic review and expert consensus. Radiotherapy and oncology, 210, 111039. (Read full publication)

    Edited Book

    1. Gaffney DK, Shrieve DC, Anker CJ, Buyyounouski MK, Kong F, Hitchcock YJ, Tward J (2012). Radiation Oncology: Imaging and Treatment.

    Book Chapter

    1. Jonathan D. Tward, Christopher J. Anker, David K. Gaffney and Glen M. Bowe (2012). Radiation Therapy and Skin Cancer.
    2. Ellen Cooke, Jonathan D. Tward, Dennis C. Shriev (2011). Anus and Rectum.
    3. Jonathan D. Twar (2016). Prostate Cancer Bone Metastasis.
    4. Hilary P. Bagshaw, Jonathan D. Twar (2016). Current and Emerging Modalities.

    Editorial

    1. Spratt DE, Tward J (2020). Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy. International journal of radiation oncology, biology, physics, 108(4), 899-902. (Read full publication)

    Letter

    1. Shprecher DR, Grossmann KF, Tward J (2014). Sustained remission of Parkinson disease associated melanoma with immunotherapy. Parkinsonism & related disorders, 20(9), 1027-9. (Read full publication)
    2. Tward J, Lenz (2023). In Regard to Dess. International journal of radiation oncology, biology, physics, 115(1), 261-263. (Read full publication)

    Abstract

    1. Tward JD, Furie, B.C., Jacobs, M., Furie, (2000). A nine amino acid motif is sufficient to direct gamma carboxylation in-vitro. Blood, 96(11),
    2. Lee, C.M., MacDonald, K.,Tward JD, Shrieve, D.C., Szabo, A., Gaffney, D.K (2006). Patterns of care analysis of adjuvant therapy in the United States for stage I-II endometrial adenocarcinoma: A surveillance, epidemiology, and end results (SEER) population analysis. Gynecologic oncology, 101(1, Supp 1),
    3. Lavey, R.S., Tward JD, Li, L.T., Brooks, J., McBride, W.H., Dempsey, W.H., Dewhirst, M.W., Brizel, D.M (1994). Hematocrit is significantly associated with the oxygenation of murine Fsa tumors. International journal of radiation oncology, biology, physics, 31(Supplement),
    4. Tward J.D., J.E. Sylvester, P.D. Grimm, D.C. Shriev (2008). The Risk of Second Primary Malignancies Following Brachytherapy Monotherapy, External Beam Plus Brachytherapy, or Radical Prostatectomy for Prostate Cancer. International journal of radiation oncology, biology, physics, 72(1 supp 1), S94.
    5. K. De Amorim Bernstein,Tward J.D., D.C. Shriev (2008). Patterns of Care for Prostate Cancer in the USA: Results from the SEER Database. International journal of radiation oncology, biology, physics, 72(1 Supp 1), S134.
    6. B.J. Salter, B. Wang, M. Szegedi, Tward J.D., D.C. Shriev (2008). Prostate Displacement during and after Transabdominal Ultrasound (US) Guidance, Monitored by a Real-time Tracking System. International journal of radiation oncology, biology, physics, 72(1 Supp 1), S146-S147.
    7. A.T. Shivnani, C.M. Lee,Tward J.D., O. Macdonald, L.L. Munoz, C. Crane, M.S. Talamonti, W. Smal (2007). Survival Outcomes for Adjuvant Radiation Therapy Versus no Radiation Therapy in Extrahepatic Cholangiocarcinoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis. International journal of radiation oncology, biology, physics, 69(3, Supp 1), S283.
    8. C.M. Lee, A. Szabo, D.C. Shrieve, O.K. Macdonald,Tward J.D., D.K. Gaffne (2006). External Beam Radiation With or Without Vaginal Brachytherapy in Stage IC-II Endometrial Adenocarcinoma Provides a Survival Advantage: A Surveillance, Epidemiology, and End Results (SEER) Population Analysis. International journal of radiation oncology, biology, physics, 66(3 Supp 1), S39-S40.
    9. L.J. Hazard, Tward J.D., J. O’Connor, D. Shriev (2006). Pre and Post-Operative Radiation Therapy is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma: Results of a Study From the Surveillance, Epidemiology, and End Results (SEER) Registry Data. International journal of radiation oncology, biology, physics, 66(3, Supp 1), S81-83.
    10. O.K. Macdonald, C.M. Lee,Tward J.D., C.D. Chappell, D.K. Gaffne (2006). Malignant Phyllodes Tumor of the Female Breast: Determinants of Cause-Specific Survival From the Surveillance, Epidemiology, and End Results: (SEER) Program. International journal of radiation oncology, biology, physics, 66(3, Supp 1), S212.
    11. Tward J.D., A. Szabo, R. Orlandi, L. Dahlstrom, D.C. Shrieve, Y.J. Hitchcoc (2006). Relative Contributions of Radiation and Platinum-Based Chemotherapy to Sensorineural Hearing Loss in Head and Neck Cancer PatientsInternational Journal of Radiation Oncology*Biology*Physics, Volume 66, Issue 3, Supplement 1, 1 November 2006, Page S188. International journal of radiation oncology, biology, physics, 66(3, Supp 1), s188.
    12. Y.J. Hitchcock, K. Morton,Tward J.D., J.M. Hoffman, P. Sharma, B. Bentz, D.C. Shriev (2006). The Application of [18FDG] PET/CT in Treatment Planning and Response Evaluation for Patients Undergoing Radiotherapy for Head and Neck Cancer. International journal of radiation oncology, biology, physics, 66(3, Supp 1), S433-S434.
    13. A.P. Brown,Tward J.D., J. Chen, D.C. Shrieve, Y.J. Hitchcoc (2006). The Risk of Development and Factors Affecting the Pattern of Secondary Cancers Following Thyroid Cancer Diagnosis. International journal of radiation oncology, biology, physics, 66(3, Supp 1), S434.
    14. E. Crawford, N., Shore, P. Scardino, J. Davis, JD Tward, K. Moyes, L. Fitzgerald, S. STone, M. Brawe (2014). CCP Score Stratifies Risk for Prostate Cancer Patients at Biopsy: Initial Commercial Results. International journal of radiation oncology, biology, physics, 90(1), s433.
    15. vj gonzalez, c hullett, l Burt, P Rassiah, v Sarkar, JD Tward, LJ Hazard, JY Huang, BJ Salter, DK Gaffne (2013). Impact of Prone Versus Supine Positioning on Small Bowel Dose With Pelvic IMRT. International journal of radiation oncology, biology, physics, 87(2), s680.
    16. N. Vudarla, I. Jawed, H. Kaya,Tward J.D., O. K. Macdonald, D. Martincic, D. K. Gaffney, A. T. Shivnani, T. L. Odom- Maryon, and C. M. Le (2007). Survival and secondary malignancy rates for adjuvant radiation therapy versus observation in stage I testicular seminoma: A Surveillance, Epidemiology, and End Results (SEER) analysis. Journal of clinical oncology, 25(18S),
    17. I. Jawed, C. M. Lee,Tward J.D., O. K. Macdonald, D. Martincic, N. Vudarla, R. K. Fairbanks, and H. Kay (2007). Survival outcomes for multiple myeloma over three decades: A Surveillance, Epidemiology, and End Results (SEER) analysis. Journal of clinical oncology, 25(18s),
    18. Jonathan D Tward, Lindsay M Burt, Dennis C Shriev (2015). Definitive treatment of localized prostate cancer: Time and geographic trends. presented at the Genitourinary Cancers Symposium. Journal of clinical oncology, 33,
    19. E. David Crawford, Neal Shore, Peter T. Scardino, John W. Davis, Jonathan D. Tward, Lowndes Harrison, Brent Evans, Lisa Fitzgerald, Steven Stone, Michael K. Brawe (2015). Performance of CCP assay in an updated series of biopsy samples obtained from commercial testing. presented at: Genitourinary Cancers Symposium. Journal of clinical oncology, 33,
    20. Cameron S. Thorpe, Jeremy B. Myers, Dennis C. Shrieve, Jonathan D. Twar (2015). Grade 3 or higher morbidity requiring urologic surgical management following curative-intent radiotherapy of localized prostate cancer: Patient characteristics. presented at: Genitourinary Cancers Symposium. Journal of clinical oncology, 33,
    21. Lindsay M.Burt, Dennis C. Shrieve, Jonathan D. Twar (2015). Prostate patterns of care. Journal of clinical oncology, 33,
    22. E. Crawford, N. Shore, P. Scardino, J David, JD Tward, L Harrison, K Moyes, L Fitzgerald, S Stone, M. Brawe (2014). CCP score and risk stratification for prostate cancer patients at biopsy: Presented at the Genitourinary Cancers Symposium. Journal of clinical oncology, 32,
    23. M Szegedi,P Rassiah-Szegedi, Y Huang, JD Tward, H Zhao, D Shrieve, and B Salte (2010). Post Implant Dosimetry for I 125 and Pd 103 Anchor and Non Anchor Seeds. Medical physics, 37(6), 3201.
    24. P Rassiah-Szegedi, B Wang, JD Tward, M Szegedi, H Zhao, and B Salte (2009). Dosimetric Feasibility of Patient-Specific Margins for Prostate Patients Using a Wireless Localization and Tracking System. Medical physics, 36(6), 2497.
    25. BJ Salter, Martin Szegedi, B Wang, JD Twar (2013). Presentation of a New Intrafractional Prostate Monitoring Method with Ultrasound Image Guidance During Radiotherapy Treatment. Medical physics, 40(6), 375.
    26. B Wanfg, V Sarkar, P Rassiah, H Zhao, YH Huang, M Szegedi, DC Shrieve, JD Tward, BJ Salte (2013). Direct Clinical Comparison of 2D Versus 3D Transabdominal Ultrasound Image Guidance Methods for Prostate Radiotherapy Treatment. Medical physics, 40(6), 375.
    27. Yu-Huei Jessica Huang, Jonathan D Tward, Prema Rassiah, Hui Zhao, Vikren Sarkar, L Huang, Martin Szegedi, Kristine E. Kokeny, Bill J Salte (2015). Feasibility of MRI-Based Preplan On Low Dose Rate Prostate Brachytherapy. Medical physics, 42(6), 331906/.
    28. Tward JD, Szabo, A., Gaffney, D.K., Shrieve, D. (2005). Does Age at Diagnosis Affect Outcome for Men Treated by Brachytherapy Versus Surgery for Clinically Localized Prostate Cancer?. Brachytherapy, 4(2), 79-120.
    29. Frandsen J, Orton A, Shrieve DC, Tward (2016). Risk of Death from Prostate Cancer with and without Definitive Local Therapy When Primary or Secondary Gleason Pattern 5 Is Present: A Seer Analysis. Brachytherapy, 15, s202-203.
    30. B.J. Salter, B. Wang, J.D. Tward, D.C. Shriev (2009). Investigation of Potential Interference of 3 Piece Penile Prostheses with Electromagnetic Localization System. 75(3), S605-S606.
    31. Tward JD, Shrieve, D.C., Szabo, A., Gaffney, D. (2005). Does Radiotherapy Alter the Pattern of Secondary Malignancies after the Treatment of Non-Hodkin’s Lymphoma. 1(1), 1.
    32. Tward JD, Shrieve, D.C (2006). The Risk of Development and Factors Affecting the Pattern of Secondary Cancers Following Diagnosis of Wilm’s Tumor. 1(1),
    33. E.W. Cooke, D.C. Shrieve, J.D. Twar (2009). Pathologic Staging Results in Substantially Higher Risk-stratification Compared with that Predicted by Clinical Risk-stratification in Men with Adenocarcinoma of the Prostate. 75(3), S297-S298.
    34. Lavey, R.S., Li, L.T., Bublick, I., Tward JD, McBride, W.H (1995). Elevation of hematocrit by recombinant human erythropoietin (r-HuEPO) improves tumor oxygenation. 1(1),
    35. Price, M., Tward JD, Li, L.T., McBride, W.H., Lavey, R.S (1994). Effect of nicotinamide and pentoxyfylline on normal tissue and Fsa tumor oxygenation.
    36. Tward JD, Furie, B.C., Bouchard, B.A., Jacobs, M., Furie, B (1998). The vitamin K-dependent gamma glutamyl carboxylase recognition sequence: refinement of the model. 92(Supp),
    37. Lavey, R.S., Tward JD, Li, L.T., McBride, W. (1994). Interactive effects of interleukin-2 and radiation on pulmonary metastases and normal tissue function.
    38. Tward JD, Furie, B.C., Bouchard, B.A., Jacobs, M., Furie, B (1997). Other amino acids than phenylalanine at position –16 in the carboxylation recognition site in the prothrombin propeptide can support gamma-carboxylation. 90(Supp),
    39. Tward JD, Hitchcock YJ, Sharma P, Shrieve D (2007). Overall and Cause-Specific Survival for Patients Undergoing Lobectomy, Near-Total, or Total Thyroidectomy for Differentiated Thyroid Cancer: Is there a Difference?. 1(1),
    40. Salama M., Ho A., Tward JD., Gaffney DK, Perkins S (2008). BCL2 expression in primary cutaneous follicle center lymphoma: clinicopathologic study of 15 cases. 1(1),
    41. Tward JD, Stephenson R, Dechet C, Shrieve D (2008). Overall and cause-specific survival comparison in men undergoing prostatectomy versus external beam radiotherapy for prostate cancer with seminal vesicle invasion. 1(1),
    42. Tward JD, Cachoeira CV, Salama ME, Lee RJ, Bowen G, Perkins SL, Glenn M, Confer M, Gaffney D (2008). Survival and Recurrence in Non-Mycosis Fungoides Primary Cutaneous Lymphoma. 1(1),
    43. M.E. Montejo, B. Bentz, J. Hunt, J. Tward, D.C. Shrieve, Y.J. Hitchcoc (2009). IMRT with Simultaneous Integrated Boost (IMRT-SIB) Radiotherapy and Concurrent Cisplatin for Locoregional Advanced Squamous Cell Carcinoma of Head and Neck. 75(3), s416-s417.
    44. P. Rassiah, B. Wang, M. Szegedi, H. Zhao, Y. Huang, J.D. Tward, D.C. Shrieve, B.J. Salte (2009). Characterization of Potential Radiobiological Benefit from Design of Patient-specific Margins for Prostate Conformal Treatment using a Real Time Tracking System. 75(3), S586-S587.
    45. A.J. Ghia, D.C. Shrieve, J.D. Twar (2009). Adjuvant Radiotherapy Use and Patterns of Care Analysis for Margin Positive Prostate Adenocarcinoma with Extracapsular Extension. 75(3), S309.
    46. E.W. Cooke, D.C. Shrieve, J.D. Twar (2009). Pathologic Staging Results in Substantially Higher Risk-stratification Compared with that Predicted by Clinical Risk-stratification in Men with Adenocarcinoma of the Prostate. 75(3), S297-S298.
    47. C. Hullett, V.J. Gonzalez, L. Burt, P. Rassiah-Szegedi, V. Sarkar, J. Tward, L.J. Hazard, J. Huang, B.J. Salter, D.K. Gaffne (2012). Impact of BMI on Daily Setup Variation With Pelvic Radiation Therapy: Is Prone Positioning a Class Solution?. 84(3), s726.
    48. J.D. Tward, W.T. Lowrance, D.C. Shriev (2012). Demographics and Comparative Effectiveness of Surgery and Radiation Therapy in Men With Gleason Pattern 5 Prostate Cancer. 84(3), s386.
    49. D. Ly, D.C. Shrieve, J.D. Twar (2012). Demographics, Prognostic Factors, and Treatment Outcomes of Adrenocorticotrophic Carcinoma: A SEER Database Analysis From 1988-2008. 84(3), s424.
    50. B.E. Terakedis, M.E. Heilbrun, W.T. Lowrance, D.C. Shrieve, J.D. Twar (2012). The Effect of Prostate MRI on Cancer Staging and Radiation Therapy Treatment Recommendations. 84(3), S363-S364.
    51. J.D. Tward, D.C. Shriev (2011). Patterns of Care for Localized Prostate Cancer Stratified by Risk Group and Age at Diagnosis in the United States. 81(2), s102.
    52. M.M. Poppe, J.D. Tward, D.C. Shriev (2011). Trend of Declining Radiotherapy Use in Pediatric Low Grade Glioma. 81(2), s657.
    53. J.D. Tward, D.C. Shriev (2010). Radiotherapy is Correlated with Superior Survival in Clinically Node Positive Prostate Cancer. 78(3), s31.
    54. L. Burt, D.C. Shrieve, J.D. Twar (2010). Stage Presentation, Care Patterns, and Treatment Outcomes for Squamous Cell Carcinoma of the Penis. 78(3), s32-s33.
    55. Y Huang, B Wang, J Tward, D Shrieve, and B Salte (2009). A Comparison of Calypso Based Localization for Post Prostatectomy Patient in the Presence of High Geometric Residual (GR) Beacon Error: Comparison/correlation with Ultrasound Alignment. 36(6), 2480.
    56. Mitchell Bassett, Darshan Patel, Benjamin Breyer, Jonathan D Tward, Cameron Thorpe, Thomas Gaither, James Hotaling, William Brant, Jeremy Myer (2016). URINARY DIVERSION FOR COMPLICATIONS OF PROSTATE CANCER RADIATION TREATMENT. 193(4), 251.
    57. Kefu Du, Chong Zhang, Angela Presson, Jonathan Tward, William Brant, Christopher Deche (2016). Kefu Du, Chong Zhang, Angela Presson, Jonathan Tward, William Brant, Christopher Dechet. 195(4), e1043.
    58. S. Francis, CJ Anker, DG Adler, JD Tward, C Kristen, DC Shriev (2013). The Effect of Stents on Acute Toxicity in Esophageal Cancer. 87(2), s296.
    59. H Bagshaw, JD Tward, D Gaffne (2013). Patterns of Care With Brachytherapy for Cervical Cancer. 87(2), s410.
    60. AE Wagner, AJ Ghia, K Kokeny, DC Shrieve, JD Twar (2013). Adjuvant Radiation Therapy After Prostatectomy: Have Randomized Clinical Trials Had Any Impact?. 87(2), s174.
    61. LM Burt, A Wagner, DC Shrieve, JD Twar (2013). Comparison of Treatments for Breast Cancer Arising After Radiation Treatment for Hodgkin Lymphoma. 87(2), s247.
    62. D Ly, CJ Anker, JD Tward, DC Shriev (2013). Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment. 87(2), s282.
    63. B O'Neil, A Presson, J Gannon, RA Stephenson, W Lowrance, C Dechet, JD Tward, J Myers,WO Bran (2013). Climacturia after Definitive Treatment of Prostate Cancer. 19(1),
    64. M. Szegedi, H. Zhao, P. Rassiah, V. Sarkar, J. Huang, L. Huang, JD Tward, K. Kokeny, B.J. Salte (2015). Clinical comparison of 2D transabdominal and 3D transperineal ultrasound image guidance methods for prostate RT. s494.
    65. ¿B.J. Salter, M. Szegedi, JD Tward, H. Zhao, V. Sarkar, P. Rassiah-Szegedi, L. Huang, J. Huan (2015). 3D transperineal ultrasound image guidance methods for prostate SBRT radiotherapy treatment. s460.
    66. Mitchell Bassett, Darshan Patel, Benjamin Breyer, Jonathan D Tward, Cameron Thorpe, Thomas Gaither, James Hotaling, William Brant, Jeremy Myer (2015). URINARY DIVERSION FOR COMPLICATIONS OF PROSTATE CANCER RADIATION TREATMENT. 193(4), e251.
    67. J.D. Tward, R. Petragallo, T. Farr, D.C. Shriev (2018). Comparative Effectiveness of Surgery versus Radiation Therapy for NCCN High and Very High Risk Prostate Cancer. 102(3), e147.
    68. Stone S, Cooperberg M, Flake, D, Davis JW, Moul JW, Tward, JD, Brawer M (2017). Evaluation of microarrays for measuring cell cycle progression (CCP) gene expression. Steven Stone, Matthew R. Cooperberg, Darl D Flake, John W. Davis, Judd W. Moul, Jonathan David Tward, Michael K. Brawer; Myriad Genetics, Inc., Salt Lake City, UT; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; Duke Cancer Institute, Duke University Medical Center, Durham, NC; University of Utah Huntsman Cancer Hospital, Salt Lake City, UT; Myriad Genetic Laboratories, Inc., Salt Lake City, UT. J Clin Oncol 35, 2017 (suppl; abstr e16566). 35(15_suppl), e16566-e16566.
    69. Shore ND, Crawford ED, Cooperberg MR, Tward JD, Kaldate RR, Stone S, Brawer M (2016). Reduction in therapeutic burden from use of CCP test in treatment decisions among newly diagnosed prostate cancer patients independent of Charlson Comorbidity Index. 34(15_suppl), e16572-e16572.
    70. Hunt T, Greenberg S, Ambrose J, O,Neil B, Tward J (2020). Factors associated with positive germline testing results in men with prostate cancer following NCCN guideline expansion. 38(suppl 6), abstr 230.
    71. Jonathan David Tward, Thorsten Schlomm, Stephen Bardot, Stephen J. Freedland, Lauren Lenz, Todd Cohen, Steven Stone, Jay Bishof (2020). Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer. 38(Suppl 6), abstr 346.
    72. Sumati Gupta, Benjamin Louis Maughan, Christopher B. Dechet, William Thomas Lowrance, Brock O Neil, Kristine E. Kokeny, Shane Lloyd, Jonathan David Tward, Kenneth M. Boucher, Neeraj Agarwa (2020). NEXT: A phase II, open-label study of nivolumab adjuvant to chemoradiation in patients (pts) with localized muscle invasive bladder cancer. 38(Suppl 6), Abstr tps605.
    73. Praful Ravi, Gregory Russell Pond, Leonidas Nikolaos Diamantopoulos, Rohit K. Jain, William Paul Skelton, Sumati Gupta, Jonathan David Tward, Kathleen Olson, Parminder Singh, Camilla Marisa Grunewald, Guenter Niegisch, Jae-Lyun Lee, Andrea Gallina, Marco Bandini, Andrea Necchi, Matthew Mossanen, Bradley Alexander McGregor, Catherine Curran, Petros Grivas, Guru Sonpavde (2020). Dissecting outcomes of patients (pts) with <ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration. 38(suppl), abstr 5043.
    74. Rebecca Levin-Epstein, Tahmineh Romero, Jessica Karen Wong, Kiri Cook, Robert Timothy Dess, Daniel Eidelberg Spratt, Brian Joseph Moran, Gregory Stephen Merrick, Phuoc T. Tran, David Jeffrey Demanes, Brad J. Stish, Daniel J. Krauss, Trude Baastad Wedde, Wolfgang Lilleby, Richard Stock, Jonathan David Tward, Michael L. Steinberg, Eric M. Horwitz, Rahul D. Tendulkar, Amar Upadhyaya Kisha (2020). Impact of initial treatment selection on clinical outcomes after biochemical failure in radiorecurrent high-risk prostate cancer. 38(Suppl 6), abstr 208.

    Other

    1. Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples A (2021). Impact of the COVID-19 pandemic on exercise habits among cancer patients. Research square, (Read full publication)
    2. Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan A (2021). Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA network open, 4(12), e2138550. (Read full publication)

    Video/Film/CD/Web/Podcast

    1. Jonathan Twar (2015). Abbreviated Course ADT for Prostate Cancer.
    2. Jonathan Twar (2014). Is Death From Prostate Cancer the Right Clinical Endpoint to Guide Screening and Treatment Choices?.

  • News & Podcasts

    Huntsman Cancer Institute News

    Podcasts